1. Quick Facts
Category: Growth Hormone Secretagogue Stack
Risk Level: Moderate/High
Research Status: Emerging Research
Administration: Subcutaneous Injection
Typical Frequency: Nightly (No DAC) or Weekly/Twice Weekly (DAC)
Estimated Half-Life: Variable Depending on DAC vs No DAC Formulation
Primary Research Interest: HGH Support / Recovery / Body Composition / Sleep Support
This material is provided strictly for educational and informational purposes related to peptide research and endocrine compounds. CJC-1295 / Ipamorelin is a biologically active peptide stack capable of significantly altering growth hormone and IGF-1 signaling pathways. Information presented here should not be interpreted as medical advice, treatment recommendations, or encouragement of unsupervised use.
2. Summary
CJC-1295 / Ipamorelin is a peptide stack designed to stimulate endogenous growth hormone release through two complementary signaling pathways. CJC-1295 acts through Growth Hormone Releasing Hormone (GHRH) receptors, while Ipamorelin acts through ghrelin receptor pathways.
The combination has become one of the most widely discussed growth hormone secretagogue stacks within peptide communities due to its potential to support recovery, sleep quality, body composition, and growth hormone signaling without the use of exogenous HGH.
What People Commonly Claim
- Creates synergistic HGH release
- Provides many benefits of HGH without using HGH itself
- Improves sleep quality
- Accelerates recovery
- Promotes fat loss
- Supports lean muscle gain
- Produces a more natural growth hormone profile
What the Literature Actually Shows
- GHRH analogs and growth hormone secretagogues stimulate growth hormone release through complementary receptor systems.
- The biological rationale for combining the compounds is strong.
- Human studies directly evaluating the CJC-1295 / Ipamorelin combination remain limited.
- Many commonly cited benefits are inferred from growth hormone physiology and individual compound research rather than controlled trials of the stack itself.
- Long-term outcome data remain limited.
CKF Note: The pharmacology of this stack depends heavily on whether the CJC-1295 component contains DAC. CJC-1295 DAC and CJC-1295 No DAC (Modified GRF 1-29) have substantially different half-lives, administration schedules, and endocrine effects. Readers should verify which version is present in any blend or protocol being discussed.
3. Reconstitution Guide
- Blend Composition: CJC-1295 5 mg / Ipamorelin 5 mg
- Blend Ratio: 1 : 1
- Total Vial Size: 10 mg total blend
- Dilutant Type: BAC Water
- Amount of Dilutant Added: 2 mL
- Final Concentration: 5.00 mg/mL total blend concentration
At this concentration:
• 500 mcg = 0.100 mL (10 units)
4. Route of Administration
CJC-1295 / Ipamorelin is most commonly administered as a subcutaneous injectable growth hormone secretagogue stack.
- Primary Route: SubQ Injection
- Preferred Timing: Commonly administered before bedtime
- Administration Notes: Evening administration is frequently discussed because endogenous growth hormone release naturally increases during sleep.
5. Typical Research Protocols
- Product Strength: 5.00 mg/mL total blend concentration
- Typical Delivered Amount: 500 mcg every PM before bedtime
- Frequency: Daily (No DAC) or Weekly/Twice Weekly (DAC)
- Cycle Length: Commonly 12–24 weeks
- Special Notes: Whether the CJC-1295 component contains DAC or No DAC dramatically changes the pharmacokinetics of the stack. No DAC versions are commonly administered daily, while DAC-containing versions are often administered once or twice weekly due to the substantially extended half-life.
6. Mechanism of Action
The stack combines two distinct growth hormone secretagogue pathways:
- CJC-1295: Stimulates Growth Hormone Releasing Hormone receptors within the pituitary gland.
- Ipamorelin: Activates ghrelin receptors associated with growth hormone pulse signaling.
Together, the combination is intended to support:
- Increased endogenous growth hormone release
- Elevated IGF-1 signaling
- Recovery pathway activation
- Lipolysis support
- Sleep and recovery quality
Because the two compounds operate through different receptor systems, many researchers view the combination as mechanistically complementary.
7. Potential Benefits
- Potential fat-loss support
- Enhanced recovery from training stress
- Improved sleep quality
- Increased endogenous HGH signaling
- Potential connective tissue support
- Possible lean body composition improvements
8. Potential Risks / Side Effects
Moderate/High
- Water retention
- Numbness or tingling
- Elevated hunger
- Insulin sensitivity changes
- Headaches
- Potential endocrine dysregulation
- Elevated IGF-1 concerns
9. Half-Life
Half-life characteristics vary dramatically depending on whether the CJC-1295 component contains DAC.
CJC-1295 No DAC (Modified GRF 1-29) typically produces short-duration pulse-based activity, while DAC-containing versions may remain biologically active for several days.
Ipamorelin itself is relatively short acting, making protocol design highly dependent upon the specific CJC formulation utilized.
10. Storage Information
- Store refrigerated before and after reconstitution
- Protect from direct light exposure
- Avoid repeated freeze-thaw cycles
- Maintain sterile handling practices during preparation
11. Contraindications / Warnings
- Active cancer or cancer history
- Pregnancy or breastfeeding
- Diabetes or insulin resistance
- Severe endocrine disorders
- Known hypersensitivity to peptide compounds
12. Further Study
The CJC-1295 / Ipamorelin stack is one of the most commonly discussed peptide combinations for growth hormone support and recovery. However, much of the rationale for combining these compounds originates from complementary physiology and individual compound research rather than direct clinical trials evaluating the stack itself.
Recommended Reading
The Development of Growth Hormone-Releasing Hormone Agonists and Antagonists
Comprehensive review of GHRH analog development, physiology, and therapeutic applications.
Growth Hormone Secretagogues: Mechanism of Action and Clinical Utility
Overview of growth hormone secretagogue physiology and receptor biology relevant to compounds such as Ipamorelin.
CKF Transparency Note: Although CJC-1295 / Ipamorelin is one of the most widely used peptide stacks in recovery and body-composition communities, high-quality human studies directly evaluating the combination remain limited. Many reported benefits are extrapolated from growth hormone physiology and individual compound research rather than controlled studies of the stack itself.
Current Evidence Gaps
- Direct human trials evaluating CJC-1295 plus Ipamorelin
- Long-term outcome data
- Comparative trials versus HGH therapy
- Recovery outcomes in healthy adults
- Muscle gain outcomes in healthy adults
- Fat-loss outcomes in healthy adults
13. Research References
- PubMed
- PubMed Central (PMC)
- NIH Publications
- Growth hormone physiology literature
- Peer-reviewed endocrinology journals
14. Last Reviewed
June 2026